About
When pharmacovigilance activities are shared with external partners, how can a Marketing Authorisation Holder (MAH) ensure that responsibilities are effectively implemented, safety information is exchanged within the required timelines and regulatory compliance can be demonstrated?
Pharmacovigilance Agreements (PVAs) are an integral part of an effective pharmacovigilance system. They define the responsibilities of each party and provide a framework for managing safety-related activities, overseeing external partners and ensuring continuity throughout the relationship.
However, even well-defined agreements can present operational challenges. Unclear reporting timelines, gaps in communication, insufficient documentation or poorly managed provider transitions may compromise compliance and the timely handling of safety information.
This practical workshop focuses on the operational implementation and oversight of PVAs in EU post-marketing pharmacovigilance for human medicines. Through real-world scenarios and guided exercises, participants will explore how to translate agreement requirements into clear processes, identify potential compliance gaps and strengthen oversight of outsourced pharmacovigilance activities.
Programme
Pharmacovigilance Agreements: responsibilities and operational scope
- The role of PVAs within the pharmacovigilance system
- Defining responsibilities between the MAH and external partners
- Mapping activities and accountability across distributors and service providers
Safety data exchange: managing timelines and responsibilities
- Establishing day zero and distinguishing partner transfer deadlines from regulatory reporting timelines
- Defining information transfer, receipt confirmation and escalation processes
- Practical exercise: reviewing and improving a safety data exchange clause
Partner oversight and inspection readiness
- Monitoring compliance with agreed responsibilities and timelines
- Identifying gaps in documentation and evidence of compliance
- Case study: investigating a late safety report and assessing corrective actions
Managing provider transitions and ensuring continuity
- Managing responsibilities during changes of pharmacovigilance service providers
- Reviewing database handover and outstanding safety cases
- Practical exercise: assessing handover readiness and defining acceptance criteria
Key takeaways and discussion
- Applying a practical checklist to review the operational adequacy of PVAs
- Knowledge check and Q&A
This course is designed for Pharmacovigilance, Drug Safety, Quality Assurance and Regulatory Affairs professionals involved in the implementation, management or oversight of Pharmacovigilance Agreements.
It is also relevant for professionals responsible for vendor management, distribution and external partnerships who need to ensure that pharmacovigilance responsibilities are clearly defined, effectively implemented and appropriately monitored.
Participant’s experience
Basic familiarity with post-marketing drug safety reporting is helpful. Participants can complete all exercises without prior experience drafting agreements.
A live online workshop combining short explanations, polls, breakout discussions and an inspection simulation. Participants rewrite a clause, compare it with a model answer and apply a review checklist to a provider handover.
Lecturers
Andrés Gola Isasi
Andres Gola Isasi is a Life Science Regulatory Compliance professional with extensive experience in the pharmaceutical, biotechnology and medical device industries. His expertise covers Regulatory Affairs, Quality Assurance, GMP compliance, investigations, Root Cause Analysis, CAPA systems, Human Factors and regulatory inspections.
Throughout his career, he has supported international life science organisations in quality and regulatory projects, including deviation investigations, CAPA improvement, inspection readiness, remediation activities and quality-system optimisation. He also combines his consulting experience with university teaching and professional training in Regulatory Affairs, Quality and Project Management.
Online Training – 1 module
22 March 2027 from 2:00 pm to 6:00 pm CET
Few days before the online training you will receive all details about the connection.
The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.
Early Bird: € 525,00* (until 1 March 2027)
Ordinary: € 655,00*
Freelance – Individual – Academy – Public Administration: € 435,00*
* for Italian companies: +22% VAT
The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.
Francesca Archetti
Marketing & Sales Specialist
At the end of the training, you will be able to